Tags

Type your tag names separated by a space and hit enter

Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
Fertil Steril. 2010 Jun; 94(1):167-72.FS

Abstract

OBJECTIVE

To compare the outcomes of protocols for ovarian stimulation with recombinant hCG microdose, with GnRH agonists and antagonists for pituitary suppression.

DESIGN

Prospective nonrandomized clinical trial.

SETTING

A private assisted reproduction center.

PATIENT(S)

We studied 182 patients undergoing intracytoplasmic sperm injection (ICSI) cycles, allocated into two groups: GnRH agonist group, in which patients received a GnRH agonist (n = 73), and a GnRH antagonist group, in which patients were administered a GnRH antagonist for pituitary suppression (n = 109).

INTERVENTION(S)

Pituitary suppression with GnRH agonist or GnRH antagonist. Ovarian stimulation carried out with recombinant FSH and supplemented with recombinant hCG microdose.

MAIN OUTCOME MEASURE(S)

Total dose of recombinant FSH and recombinant hCG administered; E(2) concentrations and endometrial width on the day of hCG trigger; number of follicles aspirated, oocytes and mature oocytes retrieved; fertilization, pregnancy (PR), implantation, and miscarriage rates.

RESULT(S)

The total dose of recombinant FSH and recombinant hCG administered were similar between groups, as were the E(2) concentrations and endometrial width. The number of follicles aspirated, oocytes, and metaphase II oocytes collected were also comparable. There were no statistically significant differences in fertilization, PR, implantation, and miscarriage rates in the GnRH agonist and GnRH antagonist groups.

CONCLUSION(S)

When using recombinant hCG microdose supplementation for controlled ovarian stimulation (COS), there are no differences in laboratory or clinical outcomes with the use of either GnRH antagonist or agonist for pituitary suppression.

Authors+Show Affiliations

Fertility-Assisted Fertilization Center, São Paulo, Brazil. cavagna@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

19342035

Citation

Cavagna, Mario, et al. "Supplementation With a Recombinant Human Chorionic Gonadotropin Microdose Leads to Similar Outcomes in Ovarian Stimulation With Recombinant Follicle-stimulating Hormone Using Either a Gonadotropin-releasing Hormone Agonist or Antagonist for Pituitary Suppression." Fertility and Sterility, vol. 94, no. 1, 2010, pp. 167-72.
Cavagna M, Maldonado LG, de Souza Bonetti TC, et al. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression. Fertil Steril. 2010;94(1):167-72.
Cavagna, M., Maldonado, L. G., de Souza Bonetti, T. C., de Almeida Ferreira Braga, D. P., Iaconelli, A., & Borges, E. (2010). Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression. Fertility and Sterility, 94(1), 167-72. https://doi.org/10.1016/j.fertnstert.2009.02.075
Cavagna M, et al. Supplementation With a Recombinant Human Chorionic Gonadotropin Microdose Leads to Similar Outcomes in Ovarian Stimulation With Recombinant Follicle-stimulating Hormone Using Either a Gonadotropin-releasing Hormone Agonist or Antagonist for Pituitary Suppression. Fertil Steril. 2010;94(1):167-72. PubMed PMID: 19342035.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression. AU - Cavagna,Mario, AU - Maldonado,Luiz Guilherme Louzada, AU - de Souza Bonetti,Tatiana Carvalho, AU - de Almeida Ferreira Braga,Daniela Paes, AU - Iaconelli,Assumpto,Jr AU - Borges,Edson,Jr Y1 - 2009/04/01/ PY - 2008/10/28/received PY - 2009/02/16/revised PY - 2009/02/25/accepted PY - 2009/4/4/entrez PY - 2009/4/4/pubmed PY - 2010/6/18/medline SP - 167 EP - 72 JF - Fertility and sterility JO - Fertil. Steril. VL - 94 IS - 1 N2 - OBJECTIVE: To compare the outcomes of protocols for ovarian stimulation with recombinant hCG microdose, with GnRH agonists and antagonists for pituitary suppression. DESIGN: Prospective nonrandomized clinical trial. SETTING: A private assisted reproduction center. PATIENT(S): We studied 182 patients undergoing intracytoplasmic sperm injection (ICSI) cycles, allocated into two groups: GnRH agonist group, in which patients received a GnRH agonist (n = 73), and a GnRH antagonist group, in which patients were administered a GnRH antagonist for pituitary suppression (n = 109). INTERVENTION(S): Pituitary suppression with GnRH agonist or GnRH antagonist. Ovarian stimulation carried out with recombinant FSH and supplemented with recombinant hCG microdose. MAIN OUTCOME MEASURE(S): Total dose of recombinant FSH and recombinant hCG administered; E(2) concentrations and endometrial width on the day of hCG trigger; number of follicles aspirated, oocytes and mature oocytes retrieved; fertilization, pregnancy (PR), implantation, and miscarriage rates. RESULT(S): The total dose of recombinant FSH and recombinant hCG administered were similar between groups, as were the E(2) concentrations and endometrial width. The number of follicles aspirated, oocytes, and metaphase II oocytes collected were also comparable. There were no statistically significant differences in fertilization, PR, implantation, and miscarriage rates in the GnRH agonist and GnRH antagonist groups. CONCLUSION(S): When using recombinant hCG microdose supplementation for controlled ovarian stimulation (COS), there are no differences in laboratory or clinical outcomes with the use of either GnRH antagonist or agonist for pituitary suppression. SN - 1556-5653 UR - https://www.unboundmedicine.com/medline/citation/19342035/Supplementation_with_a_recombinant_human_chorionic_gonadotropin_microdose_leads_to_similar_outcomes_in_ovarian_stimulation_with_recombinant_follicle_stimulating_hormone_using_either_a_gonadotropin_releasing_hormone_agonist_or_antagonist_for_pituitary_suppression_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(09)00502-0 DB - PRIME DP - Unbound Medicine ER -